Article thumbnail

Advances in Wound Healing: A Review of Current Wound Healing Products

By Patrick S. Murphy and Gregory R. D. Evans


Successful wound care involves optimizing patient local and systemic conditions in conjunction with an ideal wound healing environment. Many different products have been developed to influence this wound environment to provide a pathogen-free, protected, and moist area for healing to occur. Newer products are currently being used to replace or augment various substrates in the wound healing cascade. This review of the current state of the art in wound-healing products looks at the latest applications of silver in microbial prophylaxis and treatment, including issues involving resistance and side effects, the latest uses of negative pressure wound devices, advanced dressings and skin substitutes, biologic wound products including growth factor applications, and hyperbaric oxygen as an adjunct in wound healing. With the abundance of available products, the goal is to find the most appropriate modality or combination of modalities to optimize healing

Topics: Review Article
Publisher: Hindawi Publishing Corporation
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (2004). A .G a b r i e l ,M .L .P o r r i n o ,L .L .S t e p h e n s o n ,a n dW .A .Z a m -boni, “Effect of L-arginine on leukocyte adhesion in ischemiareperfusion injury,” Plastic and Reconstructive Surgery,
  2. (2002). A guide to biological skin substitutes,”BritishJournalofPlasticSurgery,v ol.55,no .3,pp .
  3. (1997). A histologic study of Dermagraft-TC in patients’ burn wounds,”
  4. (1998). A matched-pair, randomized study evaluating the efficacy and safety of acticoat silver-coated dressing for the treatment of burn wounds,”
  5. (2005). A novel approach to acute infection of the glenohumeral joint following rotator cuff repair—a case series,”
  6. (2005). A silver coated dressing reduces the incidence of early burn wound cellulitis and associated costs of inpatient treatment: comparative patient care audits,”
  7. (2007). A t i y e h ,M .C o s t a g l i o l a ,S .N .H a y e k ,a n dS .A .D i b o , “Effect of silver on burn wound infection control and healing: review of the literature,”
  8. (2007). Angiogenesis and vasculogenesis: inducing the growth of new blood vessels and wound healing by stimulation of bone marrow-derived progenitor cell mobilization and homing,”
  9. (2005). Angiogenesis, vasculogenesis, and induction of healing
  10. (2005). Are granulocyte colony-stimulating factors beneficial in treating diabetic foot infections? A meta-analysis,” Diabetes Care,
  11. (1989). Assessment of silver-coated urinary catheter toxicity by cell culture,”
  12. (2007). Bioengineered skin substitutes for the management of burns: a systematic review,”
  13. (2002). Capla et al., “Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures,”
  14. (1995). Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers,”
  15. (1997). Clinical trials of a biosynthetic temporary skin replacement, dermagraft-transitional covering, compared with cryopreserved human cadaver skin for temporary coverage of excised burn wounds,”
  16. (2002). Closure of partial-thickness facial burns with a bioactive skin substitute in the major burn population decreases the cost of care and improves outcome,”
  17. (1999). Comparative evaluation of the antimicrobial activity of
  18. (2003). e r s c o v i c i ,R .W .S a n d e r s ,J .M .S c a d u t o ,A .I n f a n t e ,a n dT . DiPasquale, “Vacuum-assisted wound closure (VAC therapy) for the management of patients with high-energy soft tissue injuries,”
  19. (2004). Endothelial progenitor cell dysfunction: a novel concept in the pathogenesis of vascular complications of type 1 diabetes,” Diabetes,
  20. (2006). Endothelial progenitor cell release into circulation is triggered by hyperoxia-induced increases in bone marrow nitric oxide,”
  21. (1997). Evaluation of hyperbaric oxygen for diabetic wounds: a prospective study,” Undersea and Hyperbaric Medicine,
  22. (2006). Granulocyte/macrophage colony-stimulating factor treatment of human chronic ulcers promotes angiogenesis associated with denovovascularendothelialgrowthfactortranscriptioninthe ulcer bed,”
  23. H a n s e n ,D .W .V o i g t ,P .W i e b e l h a u s ,a n dC .N .P a u l ,
  24. (2002). H e u g e l ,K .S .P a r k s ,S .S .C h r i s t i e ,J .F .P u l i t o
  25. (2003). Histogenesis versus wound repair: the anatomy of Integra’s properties,”
  26. (2005). Hoffs t a d ,S .M a l a y ,a n dJ .A . Berlin, “Effectiveness of recombinant human platelet-derived growth factor for the treatment of diabetic neuropathic foot ulcers,” Wound Repair and Regeneration,
  27. (2006). Hyperbaric oxygen and bone marrow-derived endothelial progenitor cells in diabetic wound healing,”
  28. (2010). Hyperbaric oxygen inhibits ischemia-reperfusion-induced neutrophil CD18 polarization by a nitric oxide mechanism,” Plastic and Reconstructive Surgery,
  29. (2010). Hyperbaric oxygen therapy facilitates healing of chronic foot ulcers
  30. (2010). Hyperbaric oxygen therapy for chronic wounds,”
  31. (2004). Hyperbaric oxygen therapy for chronic wounds,” Cochrane Database of Systematic Reviews,
  32. (1996). Hyperbaric oxygen therapy: a physiological approach to selected problem wound healing,”
  33. (2004). In vitro cytotoxicity testing of a nanocrystalline silver dressing (Acticoat) on cultured keratinocytes,”
  34. (2005). Infection and the chronic wound: af o c u so ns i l v e r ,
  35. (2007). Interactive dressings and topical agents,”
  36. (1994). L.M.DeshpandeandB.A.Chopade,“Plasmidmediatedsilver resistance in Acinetobacter baumannii,”
  37. (2004). Management of complex and pathological wounds with Integra,”
  38. (2004). Managing the open abdomen,”
  39. (2005). Mechanisms and clinical applications of the vacuum-assisted closure (VAC) device: a review,”
  40. (1984). Plasmid-determined silver resistance in Pseudomonas stutzeri isolated from a silver mine,”
  41. (2003). Promoting healing with recombinant human platelet-derived growth factor-BB in a previously irradiated problem wound,”
  42. (2006). r o p ,M .N o v a k ,S .R o d l ,B .H e l l b o m ,W .K r o e l l ,a n dW . Goessler, “Silver-coated dressing acticoat caused raised liver enzymes and argyria-like symptoms in burn patient,”
  43. (1999). Randomized, double-blind, placebo-controlled, dose-ranging study of granulocyte-macrophage colony stimulating factor in patients with chronic venous leg ulcers,” Wound Repair and Regeneration,
  44. (1998). Rapid healing of venous ulcers and lack of clinical rejection with an allogeneic cultured human skinequivalent,”Archives of Dermatology,
  45. (1997). Receptor-mediated and protein kinase-dependent growth enhancement of primary human fibroblasts by platelet activating factor,”
  46. (2008). Reperfusion-induced neutrophil CD18 polarization: effect of hyperbaric oxygen,”
  47. (1999). Safety and efficacy of TransCyte for the treatment of partial-thickness burns,”
  48. (1975). Salmonella typhimurium resistant to silver nitrate, chloramphenicol,andampicillin,”TheLancet,vol.1,no.7901,
  49. (2007). Seven years’ experience with integra as a reconstructive tool,”
  50. (2006). Silver dressings [safety and efficacy reports],” Plastic and Reconstructive Surgery,
  51. (1979). Silver-resistant enterobacteriaceae from hospital patients,”
  52. (2006). T h o m ,V .M .B h o p a l e ,O .C .V e l a z q u e z ,L .J .G o l d s t e i n
  53. (2003). The role of hyperbaric oxygen therapy in ischaemic diabetic lower extremity ulcers: a double-blind randomized-controlled trial,”
  54. (2001). The use of silver coated dressings on donor site wounds: a prospective, controlled matched pair study,”
  55. (2010). Use of Acticoat dressings in burns: what is the evidence?”
  56. Use of topical recombinant human platelet-derived growth factor BB in abdominal wound separation,”
  57. (1997). Vacuum-assisted closure: a new method for wound control and treatment: clinical experience,”
  58. (2006). Vacuum-assisted closure: state of clinic art,” Plastic and Reconstructive Surgery,
  59. (2004). Vacuumassisted closure in the management of the open abdomen:Plastic Surgery International 7 a report of a case and initial experiences,”
  60. (1969). W.Stanford,B.W.Rappole,andC.L.Fox,“Clinicalexperience with silver sulfadiazine, a new topical agent for control of pseudomonas infections in burns,”
  61. (1998). Wound management in an era of increasing bacterial antibiotic resistance: a role for topical silvertreatment,”
  62. (2007). Y.Huang,X.Li,Z.Liaoetal.,“Arandomizedcomparativetrial between Acticoat and SD-Ag in the treatment of residual burn wounds, including safety analysis,”

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.